Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Nov 4, 2026 is 10.56. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 11.16 — a change of -5.35% (lower).

EV/OCF

10.56

YoY

-5.35%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Tibet Rhodiola Pharmaceutical Holding is 2025 10.56 . EV/OCF (Enterprise Value to Operating Cash Flow) of Tibet Rhodiola Pharmaceutical Holding was 2024 11.16 . It decreases by -5.35% lower compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
44.69 CNY
Jan 1, 2019
25.78 CNY
Jan 1, 2020
29.62 CNY
Jan 1, 2021
34.62 CNY
Jan 1, 2022
14.34 CNY
Jan 1, 2023
10.70 CNY
Jan 1, 2024
11.16 CNY
Jan 1, 2025
10.56 CNY
The Tibet Rhodiola Pharmaceutical Holding EV/OCF history
YEAREV/OCFYoY
10.56-5.35%
11.16+4.29%
10.70-25.39%
14.34-58.58%
34.62+16.90%
29.62+14.86%
25.78-42.30%
44.69-68.89%
143.65+159.19%
55.42-43.68%
98.40-204.71%
-93.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co. generates revenue through the manufacture and wholesale of pharmaceutical products. The company distributes proprietary drug products and processes pharmaceuticals, serving markets across South China, North China, East China, Central China, and overseas regions. Its primary customers are pharmaceutical distributors and healthcare providers within these regions, focusing on the distribution of its proprietary drug portfolio. The firm's revenue streams are derived from the wholesale of manufactured pharmaceuticals and the processing of pharmaceutical products. It operates through a network of distributors in key Chinese regions and overseas markets, targeting healthcare institutions and pharmacies that require its proprietary drug solutions. The company's business model emphasizes regional distribution networks to reach its target segments efficiently. Tibet Rhodiola Pharmaceutical Holding Co. relies on its proprietary drug products for sales, with a strong presence in multiple Chinese regions and overseas markets. The company's revenue is driven by the distribution of these products through its established wholesale channels, catering to the healthcare sector's demand for pharmaceutical solutions in its operational areas. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Tibet Rhodiola Pharmaceutical Holding is 10.56 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Tibet Rhodiola Pharmaceutical Holding changed from 11.16 to 10.56, representing a -5.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Tibet Rhodiola Pharmaceutical Holding with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Tibet Rhodiola Pharmaceutical Holding

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding